nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—hypertension—type 2 diabetes mellitus	0.41	1	CtDrD
Methyldopa—ADRA2A—type 2 diabetes mellitus	0.191	1	CbGaD
Methyldopa—SLC15A1—Chlorpropamide—type 2 diabetes mellitus	0.0552	0.226	CbGbCtD
Methyldopa—SLC15A1—Tolbutamide—type 2 diabetes mellitus	0.0492	0.201	CbGbCtD
Methyldopa—SLC15A1—Ramipril—type 2 diabetes mellitus	0.0438	0.179	CbGbCtD
Methyldopa—SLC15A1—Nateglinide—type 2 diabetes mellitus	0.0418	0.171	CbGbCtD
Methyldopa—SLC15A1—Glyburide—type 2 diabetes mellitus	0.0282	0.115	CbGbCtD
Methyldopa—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0264	0.108	CbGbCtD
Methyldopa—DDC—nerve—type 2 diabetes mellitus	0.00209	0.174	CbGeAlD
Methyldopa—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000903	0.0752	CbGeAlD
Methyldopa—DDC—nephron tubule—type 2 diabetes mellitus	0.000815	0.0679	CbGeAlD
Methyldopa—DDC—kidney—type 2 diabetes mellitus	0.000717	0.0597	CbGeAlD
Methyldopa—DDC—cortex of kidney—type 2 diabetes mellitus	0.000698	0.0581	CbGeAlD
Methyldopa—COMT—islet of Langerhans—type 2 diabetes mellitus	0.00067	0.0557	CbGeAlD
Methyldopa—SLC15A1—nephron tubule—type 2 diabetes mellitus	0.000606	0.0505	CbGeAlD
Methyldopa—Isoprenaline—PIK3R1—type 2 diabetes mellitus	0.000575	0.243	CrCbGaD
Methyldopa—COMT—nephron tubule—type 2 diabetes mellitus	0.000539	0.0449	CbGeAlD
Methyldopa—SLC15A1—kidney—type 2 diabetes mellitus	0.000533	0.0443	CbGeAlD
Methyldopa—COMT—cardiovascular system—type 2 diabetes mellitus	0.000484	0.0403	CbGeAlD
Methyldopa—COMT—kidney—type 2 diabetes mellitus	0.000474	0.0394	CbGeAlD
Methyldopa—COMT—pancreas—type 2 diabetes mellitus	0.000471	0.0392	CbGeAlD
Methyldopa—COMT—cortex of kidney—type 2 diabetes mellitus	0.000461	0.0384	CbGeAlD
Methyldopa—DDC—liver—type 2 diabetes mellitus	0.000453	0.0377	CbGeAlD
Methyldopa—COMT—adipose tissue—type 2 diabetes mellitus	0.000427	0.0355	CbGeAlD
Methyldopa—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000341	0.0284	CbGeAlD
Methyldopa—SLC15A1—liver—type 2 diabetes mellitus	0.000337	0.028	CbGeAlD
Methyldopa—COMT—liver—type 2 diabetes mellitus	0.000299	0.0249	CbGeAlD
Methyldopa—ADRA2A—pancreas—type 2 diabetes mellitus	0.00024	0.02	CbGeAlD
Methyldopa—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000235	0.0196	CbGeAlD
Methyldopa—Droxidopa—ADRB3—type 2 diabetes mellitus	0.000229	0.0967	CrCbGaD
Methyldopa—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000217	0.0181	CbGeAlD
Methyldopa—Isoprenaline—ADRB3—type 2 diabetes mellitus	0.000208	0.0879	CrCbGaD
Methyldopa—Norepinephrine—ADRB3—type 2 diabetes mellitus	0.000192	0.0814	CrCbGaD
Methyldopa—Epinephrine—ADRB3—type 2 diabetes mellitus	0.000175	0.0739	CrCbGaD
Methyldopa—Levonordefrin—ADRA2A—type 2 diabetes mellitus	0.000147	0.0621	CrCbGaD
Methyldopa—Mesalazine—PPARG—type 2 diabetes mellitus	0.000146	0.0619	CrCbGaD
Methyldopa—Droxidopa—ADRA2A—type 2 diabetes mellitus	0.000104	0.0438	CrCbGaD
Methyldopa—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.000101	0.00112	CcSEcCtD
Methyldopa—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000101	0.00112	CcSEcCtD
Methyldopa—Jaundice—Losartan—type 2 diabetes mellitus	0.0001	0.0011	CcSEcCtD
Methyldopa—Mental disorder—Valsartan—type 2 diabetes mellitus	9.98e-05	0.0011	CcSEcCtD
Methyldopa—Bradycardia—Irbesartan—type 2 diabetes mellitus	9.97e-05	0.0011	CcSEcCtD
Methyldopa—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	9.97e-05	0.0011	CcSEcCtD
Methyldopa—Mental disorder—Orlistat—type 2 diabetes mellitus	9.86e-05	0.00109	CcSEcCtD
Methyldopa—Oedema—Glyburide—type 2 diabetes mellitus	9.81e-05	0.00108	CcSEcCtD
Methyldopa—Vomiting—Repaglinide—type 2 diabetes mellitus	9.8e-05	0.00108	CcSEcCtD
Methyldopa—Hepatitis—Irbesartan—type 2 diabetes mellitus	9.79e-05	0.00108	CcSEcCtD
Methyldopa—Eosinophilia—Ramipril—type 2 diabetes mellitus	9.77e-05	0.00108	CcSEcCtD
Methyldopa—Flatulence—Valsartan—type 2 diabetes mellitus	9.77e-05	0.00108	CcSEcCtD
Methyldopa—Rash—Repaglinide—type 2 diabetes mellitus	9.72e-05	0.00107	CcSEcCtD
Methyldopa—Dermatitis—Repaglinide—type 2 diabetes mellitus	9.71e-05	0.00107	CcSEcCtD
Methyldopa—Pancreatitis—Ramipril—type 2 diabetes mellitus	9.68e-05	0.00107	CcSEcCtD
Methyldopa—Leukopenia—Gliclazide—type 2 diabetes mellitus	9.66e-05	0.00106	CcSEcCtD
Methyldopa—Flatulence—Orlistat—type 2 diabetes mellitus	9.66e-05	0.00106	CcSEcCtD
Methyldopa—Headache—Repaglinide—type 2 diabetes mellitus	9.65e-05	0.00106	CcSEcCtD
Methyldopa—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	9.64e-05	0.00106	CcSEcCtD
Methyldopa—Dizziness—Rosiglitazone—type 2 diabetes mellitus	9.63e-05	0.00106	CcSEcCtD
Methyldopa—Cardiac disorder—Metformin—type 2 diabetes mellitus	9.63e-05	0.00106	CcSEcCtD
Methyldopa—Nervous system disorder—Glyburide—type 2 diabetes mellitus	9.62e-05	0.00106	CcSEcCtD
Methyldopa—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	9.62e-05	0.00106	CcSEcCtD
Methyldopa—Angina pectoris—Ramipril—type 2 diabetes mellitus	9.62e-05	0.00106	CcSEcCtD
Methyldopa—Thrombocytopenia—Glyburide—type 2 diabetes mellitus	9.61e-05	0.00106	CcSEcCtD
Methyldopa—Agranulocytosis—Losartan—type 2 diabetes mellitus	9.58e-05	0.00105	CcSEcCtD
Methyldopa—Angiopathy—Metformin—type 2 diabetes mellitus	9.41e-05	0.00104	CcSEcCtD
Methyldopa—Hypersensitivity—Glipizide—type 2 diabetes mellitus	9.39e-05	0.00103	CcSEcCtD
Methyldopa—Pancytopenia—Ramipril—type 2 diabetes mellitus	9.38e-05	0.00103	CcSEcCtD
Methyldopa—Mediastinal disorder—Metformin—type 2 diabetes mellitus	9.35e-05	0.00103	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	9.27e-05	0.00102	CcSEcCtD
Methyldopa—Hepatitis—Losartan—type 2 diabetes mellitus	9.22e-05	0.00101	CcSEcCtD
Methyldopa—Arthralgia—Gliclazide—type 2 diabetes mellitus	9.19e-05	0.00101	CcSEcCtD
Methyldopa—Myalgia—Gliclazide—type 2 diabetes mellitus	9.19e-05	0.00101	CcSEcCtD
Methyldopa—Rash—Rosiglitazone—type 2 diabetes mellitus	9.18e-05	0.00101	CcSEcCtD
Methyldopa—Constipation—Bromocriptine—type 2 diabetes mellitus	9.18e-05	0.00101	CcSEcCtD
Methyldopa—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	9.18e-05	0.00101	CcSEcCtD
Methyldopa—Nausea—Repaglinide—type 2 diabetes mellitus	9.15e-05	0.00101	CcSEcCtD
Methyldopa—Asthenia—Glipizide—type 2 diabetes mellitus	9.15e-05	0.00101	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	9.13e-05	0.001	CcSEcCtD
Methyldopa—Headache—Rosiglitazone—type 2 diabetes mellitus	9.12e-05	0.001	CcSEcCtD
Methyldopa—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	9.09e-05	0.001	CcSEcCtD
Methyldopa—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	9.09e-05	0.001	CcSEcCtD
Methyldopa—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	9e-05	0.000991	CcSEcCtD
Methyldopa—Weight increased—Ramipril—type 2 diabetes mellitus	8.98e-05	0.000989	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	8.94e-05	0.000984	CcSEcCtD
Methyldopa—Flatulence—Metformin—type 2 diabetes mellitus	8.9e-05	0.00098	CcSEcCtD
Methyldopa—Angiopathy—Irbesartan—type 2 diabetes mellitus	8.88e-05	0.000978	CcSEcCtD
Methyldopa—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	8.83e-05	0.000971	CcSEcCtD
Methyldopa—Paraesthesia—Glyburide—type 2 diabetes mellitus	8.81e-05	0.00097	CcSEcCtD
Methyldopa—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	8.77e-05	0.000965	CcSEcCtD
Methyldopa—Asthenia—Pioglitazone—type 2 diabetes mellitus	8.76e-05	0.000965	CcSEcCtD
Methyldopa—Infection—Gliclazide—type 2 diabetes mellitus	8.75e-05	0.000963	CcSEcCtD
Methyldopa—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	8.74e-05	0.000962	CcSEcCtD
Methyldopa—Diarrhoea—Glipizide—type 2 diabetes mellitus	8.72e-05	0.00096	CcSEcCtD
Methyldopa—Norepinephrine—ADRA2A—type 2 diabetes mellitus	8.71e-05	0.0368	CrCbGaD
Methyldopa—Nausea—Rosiglitazone—type 2 diabetes mellitus	8.65e-05	0.000952	CcSEcCtD
Methyldopa—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	8.64e-05	0.000951	CcSEcCtD
Methyldopa—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	8.63e-05	0.00095	CcSEcCtD
Methyldopa—Jaundice—Ramipril—type 2 diabetes mellitus	8.58e-05	0.000944	CcSEcCtD
Methyldopa—Skin disorder—Gliclazide—type 2 diabetes mellitus	8.56e-05	0.000942	CcSEcCtD
Methyldopa—Asthenia—Glimepiride—type 2 diabetes mellitus	8.54e-05	0.00094	CcSEcCtD
Methyldopa—Asthenia—Sitagliptin—type 2 diabetes mellitus	8.51e-05	0.000937	CcSEcCtD
Methyldopa—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	8.49e-05	0.000934	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	8.47e-05	0.000932	CcSEcCtD
Methyldopa—Arthralgia—Valsartan—type 2 diabetes mellitus	8.44e-05	0.000929	CcSEcCtD
Methyldopa—Myalgia—Valsartan—type 2 diabetes mellitus	8.44e-05	0.000929	CcSEcCtD
Methyldopa—Dizziness—Glipizide—type 2 diabetes mellitus	8.43e-05	0.000928	CcSEcCtD
Methyldopa—Flatulence—Irbesartan—type 2 diabetes mellitus	8.4e-05	0.000925	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	8.39e-05	0.000923	CcSEcCtD
Methyldopa—Angiopathy—Losartan—type 2 diabetes mellitus	8.36e-05	0.00092	CcSEcCtD
Methyldopa—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	8.36e-05	0.00092	CcSEcCtD
Methyldopa—Myalgia—Orlistat—type 2 diabetes mellitus	8.34e-05	0.000918	CcSEcCtD
Methyldopa—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	8.33e-05	0.000916	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	8.29e-05	0.000912	CcSEcCtD
Methyldopa—Agranulocytosis—Ramipril—type 2 diabetes mellitus	8.21e-05	0.000904	CcSEcCtD
Methyldopa—Diarrhoea—Glimepiride—type 2 diabetes mellitus	8.14e-05	0.000896	CcSEcCtD
Methyldopa—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	8.12e-05	0.000893	CcSEcCtD
Methyldopa—Vomiting—Glipizide—type 2 diabetes mellitus	8.11e-05	0.000892	CcSEcCtD
Methyldopa—Oedema—Valsartan—type 2 diabetes mellitus	8.1e-05	0.000891	CcSEcCtD
Methyldopa—Dizziness—Pioglitazone—type 2 diabetes mellitus	8.08e-05	0.000889	CcSEcCtD
Methyldopa—Infection—Valsartan—type 2 diabetes mellitus	8.04e-05	0.000885	CcSEcCtD
Methyldopa—Rash—Glipizide—type 2 diabetes mellitus	8.04e-05	0.000885	CcSEcCtD
Methyldopa—Dermatitis—Glipizide—type 2 diabetes mellitus	8.03e-05	0.000884	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	8.03e-05	0.000884	CcSEcCtD
Methyldopa—Oedema—Orlistat—type 2 diabetes mellitus	8e-05	0.00088	CcSEcCtD
Methyldopa—Headache—Glipizide—type 2 diabetes mellitus	7.99e-05	0.000879	CcSEcCtD
Methyldopa—Infection—Orlistat—type 2 diabetes mellitus	7.95e-05	0.000875	CcSEcCtD
Methyldopa—Nervous system disorder—Valsartan—type 2 diabetes mellitus	7.94e-05	0.000874	CcSEcCtD
Methyldopa—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	7.93e-05	0.000872	CcSEcCtD
Methyldopa—Paraesthesia—Gliclazide—type 2 diabetes mellitus	7.91e-05	0.000871	CcSEcCtD
Methyldopa—Flatulence—Losartan—type 2 diabetes mellitus	7.91e-05	0.00087	CcSEcCtD
Methyldopa—Epinephrine—ADRA2A—type 2 diabetes mellitus	7.91e-05	0.0334	CrCbGaD
Methyldopa—Hepatitis—Ramipril—type 2 diabetes mellitus	7.9e-05	0.00087	CcSEcCtD
Methyldopa—Aminosalicylic Acid—PTGS2—type 2 diabetes mellitus	7.88e-05	0.0333	CrCbGaD
Methyldopa—Dizziness—Glimepiride—type 2 diabetes mellitus	7.87e-05	0.000866	CcSEcCtD
Methyldopa—Skin disorder—Valsartan—type 2 diabetes mellitus	7.86e-05	0.000865	CcSEcCtD
Methyldopa—Nervous system disorder—Orlistat—type 2 diabetes mellitus	7.84e-05	0.000863	CcSEcCtD
Methyldopa—Dizziness—Sitagliptin—type 2 diabetes mellitus	7.84e-05	0.000863	CcSEcCtD
Methyldopa—Skin disorder—Orlistat—type 2 diabetes mellitus	7.77e-05	0.000855	CcSEcCtD
Methyldopa—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	7.77e-05	0.000855	CcSEcCtD
Methyldopa—Asthenia—Bromocriptine—type 2 diabetes mellitus	7.7e-05	0.000848	CcSEcCtD
Methyldopa—Myalgia—Metformin—type 2 diabetes mellitus	7.69e-05	0.000846	CcSEcCtD
Methyldopa—Headache—Pioglitazone—type 2 diabetes mellitus	7.65e-05	0.000842	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	7.64e-05	0.000841	CcSEcCtD
Methyldopa—Leukopenia—Irbesartan—type 2 diabetes mellitus	7.63e-05	0.00084	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	7.61e-05	0.000837	CcSEcCtD
Methyldopa—Nausea—Glipizide—type 2 diabetes mellitus	7.57e-05	0.000834	CcSEcCtD
Methyldopa—Vomiting—Glimepiride—type 2 diabetes mellitus	7.57e-05	0.000833	CcSEcCtD
Methyldopa—Vomiting—Sitagliptin—type 2 diabetes mellitus	7.54e-05	0.00083	CcSEcCtD
Methyldopa—Constipation—Gliclazide—type 2 diabetes mellitus	7.54e-05	0.000829	CcSEcCtD
Methyldopa—Rash—Glimepiride—type 2 diabetes mellitus	7.5e-05	0.000826	CcSEcCtD
Methyldopa—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.5e-05	0.000825	CcSEcCtD
Methyldopa—Epinephrine—TNF—type 2 diabetes mellitus	7.49e-05	0.0317	CrCbGaD
Methyldopa—Rash—Sitagliptin—type 2 diabetes mellitus	7.48e-05	0.000823	CcSEcCtD
Methyldopa—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.47e-05	0.000822	CcSEcCtD
Methyldopa—Headache—Glimepiride—type 2 diabetes mellitus	7.45e-05	0.00082	CcSEcCtD
Methyldopa—Headache—Sitagliptin—type 2 diabetes mellitus	7.43e-05	0.000818	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	7.38e-05	0.000812	CcSEcCtD
Methyldopa—Oedema—Metformin—type 2 diabetes mellitus	7.37e-05	0.000811	CcSEcCtD
Methyldopa—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7.34e-05	0.000808	CcSEcCtD
Methyldopa—Infection—Metformin—type 2 diabetes mellitus	7.32e-05	0.000806	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.29e-05	0.000802	CcSEcCtD
Methyldopa—Paraesthesia—Valsartan—type 2 diabetes mellitus	7.27e-05	0.0008	CcSEcCtD
Methyldopa—Arthralgia—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.000799	CcSEcCtD
Methyldopa—Myalgia—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.000799	CcSEcCtD
Methyldopa—Hypersensitivity—Glyburide—type 2 diabetes mellitus	7.23e-05	0.000796	CcSEcCtD
Methyldopa—Nervous system disorder—Metformin—type 2 diabetes mellitus	7.23e-05	0.000796	CcSEcCtD
Methyldopa—Thrombocytopenia—Metformin—type 2 diabetes mellitus	7.22e-05	0.000794	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	7.21e-05	0.000793	CcSEcCtD
Methyldopa—Paraesthesia—Orlistat—type 2 diabetes mellitus	7.18e-05	0.000791	CcSEcCtD
Methyldopa—Leukopenia—Losartan—type 2 diabetes mellitus	7.18e-05	0.00079	CcSEcCtD
Methyldopa—Skin disorder—Metformin—type 2 diabetes mellitus	7.16e-05	0.000788	CcSEcCtD
Methyldopa—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	7.12e-05	0.000784	CcSEcCtD
Methyldopa—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.1e-05	0.000781	CcSEcCtD
Methyldopa—Nausea—Glimepiride—type 2 diabetes mellitus	7.07e-05	0.000778	CcSEcCtD
Methyldopa—Nausea—Sitagliptin—type 2 diabetes mellitus	7.05e-05	0.000775	CcSEcCtD
Methyldopa—Asthenia—Glyburide—type 2 diabetes mellitus	7.04e-05	0.000775	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.99e-05	0.000769	CcSEcCtD
Methyldopa—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.97e-05	0.000767	CcSEcCtD
Methyldopa—Oedema—Irbesartan—type 2 diabetes mellitus	6.96e-05	0.000766	CcSEcCtD
Methyldopa—Mental disorder—Ramipril—type 2 diabetes mellitus	6.92e-05	0.000762	CcSEcCtD
Methyldopa—Constipation—Valsartan—type 2 diabetes mellitus	6.92e-05	0.000762	CcSEcCtD
Methyldopa—Infection—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.000761	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.91e-05	0.00076	CcSEcCtD
Methyldopa—Arthralgia—Losartan—type 2 diabetes mellitus	6.83e-05	0.000752	CcSEcCtD
Methyldopa—Myalgia—Losartan—type 2 diabetes mellitus	6.83e-05	0.000752	CcSEcCtD
Methyldopa—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.83e-05	0.000751	CcSEcCtD
Methyldopa—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.000751	CcSEcCtD
Methyldopa—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.81e-05	0.00075	CcSEcCtD
Methyldopa—Rash—Bromocriptine—type 2 diabetes mellitus	6.77e-05	0.000745	CcSEcCtD
Methyldopa—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.76e-05	0.000744	CcSEcCtD
Methyldopa—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.76e-05	0.000744	CcSEcCtD
Methyldopa—Headache—Bromocriptine—type 2 diabetes mellitus	6.72e-05	0.00074	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.72e-05	0.000739	CcSEcCtD
Methyldopa—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.71e-05	0.000739	CcSEcCtD
Methyldopa—Paraesthesia—Metformin—type 2 diabetes mellitus	6.62e-05	0.000729	CcSEcCtD
Methyldopa—Oedema—Losartan—type 2 diabetes mellitus	6.55e-05	0.000721	CcSEcCtD
Methyldopa—Infection—Losartan—type 2 diabetes mellitus	6.5e-05	0.000716	CcSEcCtD
Methyldopa—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.49e-05	0.000715	CcSEcCtD
Methyldopa—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.42e-05	0.000707	CcSEcCtD
Methyldopa—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.41e-05	0.000706	CcSEcCtD
Methyldopa—Nausea—Bromocriptine—type 2 diabetes mellitus	6.38e-05	0.000702	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.36e-05	0.000701	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000698	CcSEcCtD
Methyldopa—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.32e-05	0.000696	CcSEcCtD
Methyldopa—Asthenia—Gliclazide—type 2 diabetes mellitus	6.32e-05	0.000696	CcSEcCtD
Methyldopa—Constipation—Metformin—type 2 diabetes mellitus	6.3e-05	0.000694	CcSEcCtD
Methyldopa—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.25e-05	0.000688	CcSEcCtD
Methyldopa—Vomiting—Glyburide—type 2 diabetes mellitus	6.24e-05	0.000687	CcSEcCtD
Methyldopa—Rash—Glyburide—type 2 diabetes mellitus	6.19e-05	0.000681	CcSEcCtD
Methyldopa—Dermatitis—Glyburide—type 2 diabetes mellitus	6.18e-05	0.00068	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—type 2 diabetes mellitus	6.18e-05	0.0261	CrCbGaD
Methyldopa—Leukopenia—Ramipril—type 2 diabetes mellitus	6.16e-05	0.000678	CcSEcCtD
Methyldopa—Headache—Glyburide—type 2 diabetes mellitus	6.15e-05	0.000677	CcSEcCtD
Methyldopa—Norepinephrine—CYP1A2—type 2 diabetes mellitus	6.05e-05	0.0256	CrCbGaD
Methyldopa—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.03e-05	0.000664	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.01e-05	0.000661	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.97e-05	0.000657	CcSEcCtD
Methyldopa—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.96e-05	0.000656	CcSEcCtD
Methyldopa—Constipation—Irbesartan—type 2 diabetes mellitus	5.95e-05	0.000655	CcSEcCtD
Methyldopa—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.89e-05	0.000649	CcSEcCtD
Methyldopa—Paraesthesia—Losartan—type 2 diabetes mellitus	5.88e-05	0.000647	CcSEcCtD
Methyldopa—Arthralgia—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000645	CcSEcCtD
Methyldopa—Myalgia—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000645	CcSEcCtD
Methyldopa—Nausea—Glyburide—type 2 diabetes mellitus	5.83e-05	0.000642	CcSEcCtD
Methyldopa—Dizziness—Gliclazide—type 2 diabetes mellitus	5.83e-05	0.000641	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.82e-05	0.00064	CcSEcCtD
Methyldopa—Asthenia—Valsartan—type 2 diabetes mellitus	5.81e-05	0.000639	CcSEcCtD
Methyldopa—Asthenia—Orlistat—type 2 diabetes mellitus	5.74e-05	0.000632	CcSEcCtD
Methyldopa—Dopamine—CYP1A2—type 2 diabetes mellitus	5.63e-05	0.0238	CrCbGaD
Methyldopa—Oedema—Ramipril—type 2 diabetes mellitus	5.61e-05	0.000618	CcSEcCtD
Methyldopa—Vomiting—Gliclazide—type 2 diabetes mellitus	5.6e-05	0.000617	CcSEcCtD
Methyldopa—Constipation—Losartan—type 2 diabetes mellitus	5.6e-05	0.000616	CcSEcCtD
Methyldopa—Rash—Gliclazide—type 2 diabetes mellitus	5.56e-05	0.000611	CcSEcCtD
Methyldopa—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.55e-05	0.000611	CcSEcCtD
Methyldopa—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.54e-05	0.00061	CcSEcCtD
Methyldopa—Headache—Gliclazide—type 2 diabetes mellitus	5.52e-05	0.000608	CcSEcCtD
Methyldopa—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.51e-05	0.000606	CcSEcCtD
Methyldopa—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.5e-05	0.000605	CcSEcCtD
Methyldopa—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.5e-05	0.000605	CcSEcCtD
Methyldopa—Epinephrine—CYP1A2—type 2 diabetes mellitus	5.49e-05	0.0232	CrCbGaD
Methyldopa—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.47e-05	0.000602	CcSEcCtD
Methyldopa—Skin disorder—Ramipril—type 2 diabetes mellitus	5.45e-05	0.0006	CcSEcCtD
Methyldopa—Dizziness—Valsartan—type 2 diabetes mellitus	5.35e-05	0.000589	CcSEcCtD
Methyldopa—Dizziness—Orlistat—type 2 diabetes mellitus	5.29e-05	0.000582	CcSEcCtD
Methyldopa—Asthenia—Metformin—type 2 diabetes mellitus	5.29e-05	0.000582	CcSEcCtD
Methyldopa—Nausea—Gliclazide—type 2 diabetes mellitus	5.23e-05	0.000576	CcSEcCtD
Methyldopa—Body temperature increased—Losartan—type 2 diabetes mellitus	5.18e-05	0.00057	CcSEcCtD
Methyldopa—Vomiting—Valsartan—type 2 diabetes mellitus	5.15e-05	0.000567	CcSEcCtD
Methyldopa—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.13e-05	0.000564	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.11e-05	0.000563	CcSEcCtD
Methyldopa—Rash—Valsartan—type 2 diabetes mellitus	5.1e-05	0.000562	CcSEcCtD
Methyldopa—Dermatitis—Valsartan—type 2 diabetes mellitus	5.1e-05	0.000561	CcSEcCtD
Methyldopa—Vomiting—Orlistat—type 2 diabetes mellitus	5.09e-05	0.00056	CcSEcCtD
Methyldopa—Headache—Valsartan—type 2 diabetes mellitus	5.07e-05	0.000558	CcSEcCtD
Methyldopa—Diarrhoea—Metformin—type 2 diabetes mellitus	5.04e-05	0.000555	CcSEcCtD
Methyldopa—Rash—Orlistat—type 2 diabetes mellitus	5.04e-05	0.000555	CcSEcCtD
Methyldopa—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.04e-05	0.000555	CcSEcCtD
Methyldopa—Dermatitis—Orlistat—type 2 diabetes mellitus	5.04e-05	0.000555	CcSEcCtD
Methyldopa—Headache—Orlistat—type 2 diabetes mellitus	5.01e-05	0.000552	CcSEcCtD
Methyldopa—Asthenia—Irbesartan—type 2 diabetes mellitus	4.99e-05	0.000549	CcSEcCtD
Methyldopa—Dizziness—Metformin—type 2 diabetes mellitus	4.88e-05	0.000537	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.85e-05	0.000533	CcSEcCtD
Methyldopa—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.82e-05	0.000531	CcSEcCtD
Methyldopa—Nausea—Valsartan—type 2 diabetes mellitus	4.81e-05	0.000529	CcSEcCtD
Methyldopa—Constipation—Ramipril—type 2 diabetes mellitus	4.8e-05	0.000528	CcSEcCtD
Methyldopa—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000524	CcSEcCtD
Methyldopa—Nausea—Orlistat—type 2 diabetes mellitus	4.75e-05	0.000523	CcSEcCtD
Methyldopa—Asthenia—Losartan—type 2 diabetes mellitus	4.7e-05	0.000517	CcSEcCtD
Methyldopa—Vomiting—Metformin—type 2 diabetes mellitus	4.69e-05	0.000516	CcSEcCtD
Methyldopa—Rash—Metformin—type 2 diabetes mellitus	4.65e-05	0.000512	CcSEcCtD
Methyldopa—Dermatitis—Metformin—type 2 diabetes mellitus	4.64e-05	0.000511	CcSEcCtD
Methyldopa—Headache—Metformin—type 2 diabetes mellitus	4.62e-05	0.000508	CcSEcCtD
Methyldopa—Dizziness—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.000506	CcSEcCtD
Methyldopa—Diarrhoea—Losartan—type 2 diabetes mellitus	4.48e-05	0.000493	CcSEcCtD
Methyldopa—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000488	CcSEcCtD
Methyldopa—Vomiting—Irbesartan—type 2 diabetes mellitus	4.42e-05	0.000487	CcSEcCtD
Methyldopa—Rash—Irbesartan—type 2 diabetes mellitus	4.39e-05	0.000483	CcSEcCtD
Methyldopa—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.38e-05	0.000482	CcSEcCtD
Methyldopa—Nausea—Metformin—type 2 diabetes mellitus	4.38e-05	0.000482	CcSEcCtD
Methyldopa—Headache—Irbesartan—type 2 diabetes mellitus	4.36e-05	0.00048	CcSEcCtD
Methyldopa—Dizziness—Losartan—type 2 diabetes mellitus	4.33e-05	0.000477	CcSEcCtD
Methyldopa—Vomiting—Losartan—type 2 diabetes mellitus	4.16e-05	0.000458	CcSEcCtD
Methyldopa—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.14e-05	0.000455	CcSEcCtD
Methyldopa—Nausea—Irbesartan—type 2 diabetes mellitus	4.13e-05	0.000455	CcSEcCtD
Methyldopa—Rash—Losartan—type 2 diabetes mellitus	4.13e-05	0.000454	CcSEcCtD
Methyldopa—Dermatitis—Losartan—type 2 diabetes mellitus	4.12e-05	0.000454	CcSEcCtD
Methyldopa—Headache—Losartan—type 2 diabetes mellitus	4.1e-05	0.000451	CcSEcCtD
Methyldopa—Asthenia—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000443	CcSEcCtD
Methyldopa—Nausea—Losartan—type 2 diabetes mellitus	3.89e-05	0.000428	CcSEcCtD
Methyldopa—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000423	CcSEcCtD
Methyldopa—Dizziness—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000409	CcSEcCtD
Methyldopa—Epinephrine—CYP3A4—type 2 diabetes mellitus	3.64e-05	0.0154	CrCbGaD
Methyldopa—Vomiting—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000393	CcSEcCtD
Methyldopa—Rash—Ramipril—type 2 diabetes mellitus	3.54e-05	0.00039	CcSEcCtD
Methyldopa—Dermatitis—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000389	CcSEcCtD
Methyldopa—Headache—Ramipril—type 2 diabetes mellitus	3.52e-05	0.000387	CcSEcCtD
Methyldopa—Nausea—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000367	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—GNB3—type 2 diabetes mellitus	1.11e-05	0.000226	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CD36—type 2 diabetes mellitus	1.11e-05	0.000224	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	1.1e-05	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF2—type 2 diabetes mellitus	1.09e-05	0.000222	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPP2CA—type 2 diabetes mellitus	1.09e-05	0.000221	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOB—type 2 diabetes mellitus	1.08e-05	0.00022	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCC8—type 2 diabetes mellitus	1.07e-05	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CBS—type 2 diabetes mellitus	1.07e-05	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	1.07e-05	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GCGR—type 2 diabetes mellitus	1.06e-05	0.000216	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOB—type 2 diabetes mellitus	1.06e-05	0.000215	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—type 2 diabetes mellitus	1.05e-05	0.000214	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	1.05e-05	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	1.05e-05	0.000213	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MTHFR—type 2 diabetes mellitus	1.05e-05	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR5—type 2 diabetes mellitus	1.04e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	1.04e-05	0.000211	CbGpPWpGaD
Methyldopa—COMT—Metabolism—LPL—type 2 diabetes mellitus	1.03e-05	0.00021	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A2—type 2 diabetes mellitus	1.03e-05	0.000209	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COX2—type 2 diabetes mellitus	1.03e-05	0.000209	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARA—type 2 diabetes mellitus	1.03e-05	0.000209	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—C3—type 2 diabetes mellitus	1.02e-05	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	1.02e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA6—type 2 diabetes mellitus	1.01e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	1.01e-05	0.000205	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ADCY5—type 2 diabetes mellitus	1.01e-05	0.000205	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPX1—type 2 diabetes mellitus	1.01e-05	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—UCP2—type 2 diabetes mellitus	9.96e-06	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—UCP3—type 2 diabetes mellitus	9.96e-06	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSD11B1—type 2 diabetes mellitus	9.96e-06	0.000202	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AGT—type 2 diabetes mellitus	9.95e-06	0.000202	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CD36—type 2 diabetes mellitus	9.81e-06	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GIPR—type 2 diabetes mellitus	9.79e-06	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRK5—type 2 diabetes mellitus	9.79e-06	0.000199	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CALM1—type 2 diabetes mellitus	9.78e-06	0.000199	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—type 2 diabetes mellitus	9.75e-06	0.000198	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPP2CA—type 2 diabetes mellitus	9.69e-06	0.000197	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	9.69e-06	0.000197	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AGT—type 2 diabetes mellitus	9.68e-06	0.000197	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOA1—type 2 diabetes mellitus	9.64e-06	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CD36—type 2 diabetes mellitus	9.62e-06	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PPP2CA—type 2 diabetes mellitus	9.5e-06	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IAPP—type 2 diabetes mellitus	9.46e-06	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	9.4e-06	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PCK1—type 2 diabetes mellitus	9.36e-06	0.00019	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MTHFR—type 2 diabetes mellitus	9.3e-06	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	9.24e-06	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	9.18e-06	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	9.15e-06	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SRC—type 2 diabetes mellitus	9.12e-06	0.000185	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARA—type 2 diabetes mellitus	9.12e-06	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MC4R—type 2 diabetes mellitus	8.96e-06	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	8.91e-06	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—type 2 diabetes mellitus	8.88e-06	0.00018	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AGT—type 2 diabetes mellitus	8.83e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	8.8e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	8.8e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MMP1—type 2 diabetes mellitus	8.77e-06	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HK1—type 2 diabetes mellitus	8.77e-06	0.000178	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CALM1—type 2 diabetes mellitus	8.69e-06	0.000176	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—type 2 diabetes mellitus	8.66e-06	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GIP—type 2 diabetes mellitus	8.62e-06	0.000175	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOA1—type 2 diabetes mellitus	8.56e-06	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	8.54e-06	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CALM1—type 2 diabetes mellitus	8.51e-06	0.000173	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—type 2 diabetes mellitus	8.49e-06	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCKR—type 2 diabetes mellitus	8.47e-06	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSD3B2—type 2 diabetes mellitus	8.47e-06	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—KCNJ11—type 2 diabetes mellitus	8.47e-06	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPA—type 2 diabetes mellitus	8.47e-06	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOA1—type 2 diabetes mellitus	8.39e-06	0.00017	CbGpPWpGaD
Methyldopa—DDC—Metabolism—INS—type 2 diabetes mellitus	8.33e-06	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	8.31e-06	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEPR—type 2 diabetes mellitus	8.19e-06	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	8.15e-06	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GCG—type 2 diabetes mellitus	8.15e-06	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDOB—type 2 diabetes mellitus	8.12e-06	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GHRL—type 2 diabetes mellitus	8.09e-06	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	8.02e-06	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PRKCB—type 2 diabetes mellitus	8e-06	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCA—type 2 diabetes mellitus	8e-06	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—type 2 diabetes mellitus	7.98e-06	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—type 2 diabetes mellitus	7.91e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	7.83e-06	0.000159	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—type 2 diabetes mellitus	7.64e-06	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TLE4—type 2 diabetes mellitus	7.61e-06	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GLP1R—type 2 diabetes mellitus	7.55e-06	0.000153	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—type 2 diabetes mellitus	7.54e-06	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GCG—type 2 diabetes mellitus	7.4e-06	0.00015	CbGpPWpGaD
Methyldopa—COMT—Metabolism—INS—type 2 diabetes mellitus	7.39e-06	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB3—type 2 diabetes mellitus	7.33e-06	0.000149	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—type 2 diabetes mellitus	7.3e-06	0.000148	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3R1—type 2 diabetes mellitus	7.3e-06	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	7.28e-06	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CRHR1—type 2 diabetes mellitus	7.08e-06	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A2—type 2 diabetes mellitus	7.04e-06	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	7.03e-06	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—type 2 diabetes mellitus	7.01e-06	0.000142	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT2—type 2 diabetes mellitus	7.01e-06	0.000142	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AVP—type 2 diabetes mellitus	6.93e-06	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTR—type 2 diabetes mellitus	6.9e-06	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CPT1A—type 2 diabetes mellitus	6.9e-06	0.00014	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—type 2 diabetes mellitus	6.78e-06	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NAMPT—type 2 diabetes mellitus	6.77e-06	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LIPC—type 2 diabetes mellitus	6.73e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HBA1—type 2 diabetes mellitus	6.73e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCK—type 2 diabetes mellitus	6.73e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP11A1—type 2 diabetes mellitus	6.68e-06	0.000136	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—type 2 diabetes mellitus	6.68e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—type 2 diabetes mellitus	6.66e-06	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—type 2 diabetes mellitus	6.65e-06	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	6.59e-06	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC9A1—type 2 diabetes mellitus	6.56e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	6.53e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CETP—type 2 diabetes mellitus	6.49e-06	0.000132	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—type 2 diabetes mellitus	6.48e-06	0.000132	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3R1—type 2 diabetes mellitus	6.48e-06	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	6.47e-06	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	6.47e-06	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	6.38e-06	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—type 2 diabetes mellitus	6.36e-06	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3R1—type 2 diabetes mellitus	6.36e-06	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RBP4—type 2 diabetes mellitus	6.31e-06	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	6.31e-06	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AVP—type 2 diabetes mellitus	6.29e-06	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	6.29e-06	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	6.26e-06	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	6.21e-06	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMD6—type 2 diabetes mellitus	6.03e-06	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SREBF1—type 2 diabetes mellitus	6.03e-06	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SNAP25—type 2 diabetes mellitus	6.03e-06	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	5.99e-06	0.000122	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—type 2 diabetes mellitus	5.93e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CTGF—type 2 diabetes mellitus	5.92e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	5.89e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMGCR—type 2 diabetes mellitus	5.87e-06	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C3—type 2 diabetes mellitus	5.76e-06	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	5.69e-06	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	5.67e-06	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	5.62e-06	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IAPP—type 2 diabetes mellitus	5.59e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—INSR—type 2 diabetes mellitus	5.55e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2E1—type 2 diabetes mellitus	5.52e-06	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	5.47e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	5.46e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—type 2 diabetes mellitus	5.46e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A2—type 2 diabetes mellitus	5.46e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	5.45e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	5.43e-06	0.00011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	5.35e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP3A4—type 2 diabetes mellitus	5.32e-06	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C3—type 2 diabetes mellitus	5.23e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A4—type 2 diabetes mellitus	5.23e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCG—type 2 diabetes mellitus	5.23e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	5.2e-06	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	5.06e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	5.04e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	5.04e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—type 2 diabetes mellitus	4.97e-06	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.91e-06	9.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	4.89e-06	9.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.89e-06	9.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.78e-06	9.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.78e-06	9.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.72e-06	9.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	4.7e-06	9.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	4.59e-06	9.32e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	4.58e-06	9.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	4.51e-06	9.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.51e-06	9.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	4.49e-06	9.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	4.45e-06	9.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	4.43e-06	8.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	4.43e-06	8.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	4.37e-06	8.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	4.37e-06	8.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	4.3e-06	8.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	4.3e-06	8.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	4.29e-06	8.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	4.2e-06	8.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	4.18e-06	8.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	4.1e-06	8.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	4.09e-06	8.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	4.02e-06	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	4.02e-06	8.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	4.02e-06	8.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	4e-06	8.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	3.9e-06	7.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	3.85e-06	7.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.8e-06	7.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.77e-06	7.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	3.72e-06	7.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.72e-06	7.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.7e-06	7.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	3.7e-06	7.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.69e-06	7.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.65e-06	7.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	3.63e-06	7.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	3.59e-06	7.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.58e-06	7.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.54e-06	7.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	3.51e-06	7.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	3.45e-06	7.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	3.44e-06	6.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	3.43e-06	6.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	3.4e-06	6.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.36e-06	6.82e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—type 2 diabetes mellitus	3.36e-06	6.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.22e-06	6.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.16e-06	6.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	3.09e-06	6.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	3e-06	6.08e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—type 2 diabetes mellitus	2.98e-06	6.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.95e-06	5.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.94e-06	5.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	2.94e-06	5.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.94e-06	5.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	2.92e-06	5.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.89e-06	5.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.88e-06	5.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.88e-06	5.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.84e-06	5.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.71e-06	5.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	2.69e-06	5.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	2.58e-06	5.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	2.58e-06	5.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.57e-06	5.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	2.46e-06	4.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.42e-06	4.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.38e-06	4.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.38e-06	4.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.37e-06	4.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	2.36e-06	4.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.26e-06	4.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.16e-06	4.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.16e-06	4.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.03e-06	4.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.85e-06	3.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.83e-06	3.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.82e-06	3.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.73e-06	3.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.71e-06	3.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.68e-06	3.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.59e-06	3.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.55e-06	3.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.43e-06	2.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.4e-06	2.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	1.18e-06	2.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.07e-06	2.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.91e-07	2.01e-05	CbGpPWpGaD
